Citigroup Inc Uro Gen Pharma Ltd. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Citigroup Inc holds 29,277 shares of URGN stock, worth $116,522. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,277
Previous 38,010
22.98%
Holding current value
$116,522
Previous $404,000
20.05%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding URGN
# of Institutions
142Shares Held
41.6MCall Options Held
91.4KPut Options Held
42.1K-
Ubs Asset Management Americas Inc Chicago, IL4.36MShares$17.4 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.83MShares$15.3 Million0.69% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.21MShares$12.8 Million0.74% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$9.17 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$8.73 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $90.5M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...